“…It is higher than in the European population (Hasanzad et al., ). - A high prevalence (39.3%) of subjects (respectively, 24.3% homozygous T/T CYP2D6*10 and 15% heterozygous C/T CYP2D6*10 as poor and intermediate metabolizers) among Iranians; therefore, the harmful effects of drugs are relatively common (Bagheri et al., ).
- An ABCD1 mutation (c.253dup leading to p.Arg85Profs*110) was identified in 35 affected individuals (out of 96 pedigree members) among an expanded pedigree among Lurs. Therefore, the prevalence of X‐ALD is expected to be higher among consanguineous Lurs ethnicity (Mehrpour et al., ).
- ) MSH3, MSH6, APC, and PIK3CA genes are predicted to play a bigger role in the pathogenesis of colon cancer in Iranian population (Ashktorab et al., ).
- In a pilot study of Persian nephropathic cystinosis population, the common 57‐kb deletion was not observed; however, at least 50% of mutations were observed in exons 6 and 7 of CTNS (Ghazi et al., ).
- In another pilot study, the role of kidney anion exchanger 1 gene (AE1) mutations is highlighted in Iranian children with distal renal tubular acidosis (dRTA); moreover a novel mutation pattern of AE) has been reported in patients with distal renal tubular acidosis in Iran (Hooman et al., ).
- Among all Iranian patients with cystic fibrosis, just 16.6% has shown a delta F508 mutation in CFTR (either homozygote or heterozygote) (Najafi et al., ), which is different from many other populations around the world.
…”